Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers the price target from $8 to $7.
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.55) by...
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by...
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written annually fo...
